匯盈控股(00821.HK)附屬訂立分許可協議
匯盈控股(00821.HK)公布,於12月17日Vast Sea Biotechnology, Inc.、公司附屬作為許可人及分被可人訂立分許可協議,被許可人將該許可所涉之若干相關程序分授予分被許可人,包括是於美國及分許可地區製造及生產兩種藥物劑型之獨家及專屬權利,分別為有形物質之一次性滴劑及口含片,並向北美洲、歐洲聯盟、中東及阿拉伯國家聯盟所有國家分銷及銷售相關產品之獨家及專屬權利。
分被許可人須就相關產品向被許可人支付專利權費,有關專利費金額將相當於分被許可人出售相關產品之售價之5%。首12個月之最低專利費金額將為300萬美元。(el/k) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.